Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction

Area of Science:

• Cardiology
• Pharmacology
• Vascular Medicine

Background:

• Coronary microvascular dysfunction (CMD) affects 20-30% of patients, leading to worsening symptoms and reduced quality of life.
• Current anti-ischemic drug efficacy for CMD is often limited, and large-scale studies are scarce.

Purpose of the Study:

• To evaluate the effectiveness of ranolazine in managing coronary microvascular dysfunction (CMD).
• To assess ranolazine's impact on patient-reported health status, coronary arterial flow reserve (CFR), and exercise tolerance in CMD patients.

Main Methods:

• Systematic review of studies evaluating ranolazine in CMD patients.
• Analysis of ranolazine's effects on health status questionnaires, CFR measurements, and exercise test parameters.

Main Results:

• Ranolazine, when added to existing therapies, improved health status in 80% of evaluated studies.
• Significant improvements in CFR were observed in patients with low baseline values, suggesting better response in severe CMD.
• Ranolazine treatment led to increased exercise duration and time to myocardial ischemia in relevant studies.

Conclusions:

• Ranolazine demonstrates potential as an adjunctive therapy for CMD, improving key clinical and physiological parameters.
• Patients with more severe CMD may benefit more significantly from ranolazine treatment.
• Further large-scale, long-duration studies are required to establish ranolazine's efficacy as a sole agent for CMD treatment.